GBA Variants and Parkinson Disease: Mechanisms and Treatments
L Smith, AHV Schapira - Cells, 2022 - mdpi.com
The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …
maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have …
Neuropathology of incidental Lewy body & prodromal Parkinson's disease
T Koeglsperger, SL Rumpf, P Schließer… - Molecular …, 2023 - Springer
Background Parkinson's disease (PD) is a progressive neurodegenerative disorder
associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there …
associated with a loss of dopaminergic (DA) neurons. Despite symptomatic therapies, there …
[HTML][HTML] The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson's disease
DC Schöndorf, D Ivanyuk, P Baden… - Cell reports, 2018 - cell.com
While mitochondrial dysfunction is emerging as key in Parkinson's disease (PD), a central
question remains whether mitochondria are actual disease drivers and whether boosting …
question remains whether mitochondria are actual disease drivers and whether boosting …
Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism
Mutations in GBA1, the gene encoding the lysosomal enzyme β-glucocerebrosidase
(GCase), which cause Gaucher's disease, are the most frequent genetic risk factor for …
(GCase), which cause Gaucher's disease, are the most frequent genetic risk factor for …
α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models
JR Mazzulli, F Zunke, O Isacson… - Proceedings of the …, 2016 - National Acad Sciences
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by the
accumulation of protein aggregates comprised of α-synuclein (α-syn). A major barrier in …
accumulation of protein aggregates comprised of α-synuclein (α-syn). A major barrier in …
Parkinson disease
W Poewe, K Seppi, CM Tanner, GM Halliday… - Nature reviews Disease …, 2017 - nature.com
Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …
Balancing mTOR signaling and autophagy in the treatment of Parkinson's disease
The mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in
regulating cell growth, proliferation, and life span. mTOR signaling is a central regulator of …
regulating cell growth, proliferation, and life span. mTOR signaling is a central regulator of …
Cellular and molecular basis of neurodegeneration in Parkinson disease
XS Zeng, WS Geng, JJ Jia, L Chen… - Frontiers in aging …, 2018 - frontiersin.org
It has been 200 years since Parkinson disease (PD) was described by Dr. Parkinson in
1817. The disease is the second most common neurodegenerative disease characterized …
1817. The disease is the second most common neurodegenerative disease characterized …
Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons
Parkinson's disease (PD) is characterized by the accumulation of α-synuclein (α-syn) within
Lewy body inclusions in the nervous system. There are currently no disease-modifying …
Lewy body inclusions in the nervous system. There are currently no disease-modifying …
Glycosphingolipids and neuroinflammation in Parkinson's disease
K Belarbi, E Cuvelier, MA Bonte, M Desplanque… - Molecular …, 2020 - Springer
Parkinson's disease is a progressive neurodegenerative disease characterized by the loss
of dopaminergic neurons of the nigrostriatal pathway and the formation of neuronal …
of dopaminergic neurons of the nigrostriatal pathway and the formation of neuronal …